Do Not Give Tranexamic Acid for Upper GI Bleeding with Melena
Tranexamic acid should NOT be administered to this patient with melena and active upper gastrointestinal bleeding, regardless of alcohol intoxication status. The most recent high-quality evidence demonstrates no mortality benefit and increased thromboembolic risk with tranexamic acid in upper GI bleeding.
Evidence Against Tranexamic Acid Use
The 2025 French emergency medicine guidelines explicitly state that tranexamic acid should NOT be used in upper gastrointestinal hemorrhage 1. This recommendation is based on the landmark HALT-IT trial, which found tranexamic acid ineffective in reducing mortality whether or not anticoagulants were present 1.
Key Safety Concerns
Tranexamic acid increases thromboembolic events in GI bleeding:
- Deep venous thrombosis (RR 2.01) 2
- Pulmonary embolism (RR 1.78) 2
- Seizures (RR 1.73) 2
- Both venous AND arterial thrombotic events documented 3
The FDA label confirms these risks, explicitly warning that tranexamic acid may increase thromboembolic events and is contraindicated in patients with active intravascular clotting 4.
Standard Management Approach
Focus on proven interventions for upper GI bleeding:
Resuscitation and hemodynamic stabilization - Blood transfusion for hemoglobin targets, IV access, fluid resuscitation 5
Risk stratification - Use Blatchford or Rockall scores to identify high-risk patients requiring urgent intervention 6
Endoscopic therapy - This is the cornerstone of treatment for non-variceal bleeding with major stigmata (active bleeding, visible vessel, adherent clot) 5
Proton pump inhibitors - High-dose IV PPI therapy for peptic ulcer bleeding 5
Interventional radiology or surgery - For refractory bleeding 5
Alcohol Intoxication Considerations
The alcohol intoxication status does not change the recommendation against tranexamic acid. However, consider:
- Higher risk of gastric erosions and Mallory-Weiss tears in alcohol users (common causes of UGIB) 5
- Potential coagulopathy from chronic liver disease if the patient has cirrhosis
- Aspiration risk during endoscopy - may need airway protection
Special Note on Cirrhosis
If this patient has underlying cirrhosis from chronic alcohol use, the 2022 EASL guidelines specifically recommend against tranexamic acid for variceal bleeding 7. Even for non-variceal bleeding in cirrhosis, local hemostatic measures and portal pressure reduction take priority over systemic hemostatic agents 7.
When Tranexamic Acid Might Be Considered (Not This Case)
The only scenario where tranexamic acid shows potential benefit in GI bleeding is low-dose oral/enteral administration for upper GI bleeding in highly selected cases 2. However, this:
- Requires moderate-quality evidence only
- Is NOT the standard of care
- Should be confined to clinical trials per British guidelines 8
The 2019 British Society of Gastroenterology guidelines explicitly recommend confining tranexamic acid use in acute GI bleeding to clinical trials 8.
Bottom Line
Proceed with standard upper GI bleeding management without tranexamic acid. Prioritize urgent endoscopy (within 24 hours for high-risk patients), hemodynamic resuscitation, and PPI therapy. The alcohol intoxication is relevant for aspiration precautions and identifying bleeding etiology but does not alter the contraindication to tranexamic acid 5, 1.